Adneuris Therapeutics Presents Novel Data on Lead Candidate, Cebranopadol for the Treatment of Moderate-to-Severe Acute Pain at PAINWeek 2026

ConferenceCebranopadolPositive

AI Analysis

Summary

Adneuris Therapeutics presented new abuse potential data for cebranopadol at PAINWeek 2026, demonstrating lower abuse potential compared to Schedule II and IV opioids, leveraging its dual NOP/MOP receptor mechanism.

Outcome Details

Abuse potential data presented showing cebranopadol may have lower abuse potential than Schedule II and IV pain drugs

Importance:5/10

Sentiment:

0.60

pain managementabuse potentialdual NOP/MOP mechanismPAINWeek conference

Related Companies

$DMIIR

Read the original article

Published by GlobeNewswire Clinical Studies on September 10, 2026 3:38 PM

Read Original